AGC Biologics partners Evax, advancing promising equine allergy vaccine candidate

KUALA LUMPUR, Sept 8 (Bernama) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new partnership with Evax, a developer of equine vaccines to treat chronic diseases, respiratory disorders and allergies.

According to a statement, through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply cGMP support for the pivotal studies.

AGC Biologics is providing services at its Heidelberg facility using microbial-based protein biologics systems. The project covers Process Development and Clinical Manufacturing for the Evax Antigen-VLP Conjugate product.

“The specialised work that Evax is performing for the equine market is truly unique and we are happy to be supporting this important programme,” said Chief Business Officer of AGC Biologics, JB Agnus.

“This partnership shows the true depth of our services. Thanks to our strong global network, we feel we can support any clinical and commercial projects with reliable, innovative and cost competitive solutions.”

Meanwhile, Chief Executive Officer and Founder of Evax, Dr Antonia Gabriel said: “For many equine diseases only limited therapeutic treatment options are available with sometimes poor efficacy.

“We believe in this product and are ready to display its abilities in the clinical stages. Further, AGC Biologics and the capabilities at its Heidelberg site are an ideal fit to help guide us through this important phase of the journey.”

The Evax drug candidate is focused on treating summer eczema, also called sweet itch or insect bite hypersensitivity (IBH), which is one of the most prevalent allergic skin diseases in horses. It manifests as chronic relapsing seasonal allergic dermatitis (inflammatory reaction of the skin).

More details at www.agcbio.com.

-- BERNAMA